Keywords: Takeda, Alinamin-F5, Manufacturing, Corrective action

Takeda called on to take corrective action over Alinamin-F5 marketing and manufacturing

Article | 15 February 2013

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) revealed it has received an Order for Corrective Action regarding the manufacturing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Takeda Pharmaceuticals

Go to company listing

Related Drugs

Alinamin-F5

Go to drug listing